Research ArticlePsoriatic Arthritis
Open Access
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros and Olivier Chambenoit
The Journal of Rheumatology August 2022, 49 (8) 894-902; DOI: https://doi.org/10.3899/jrheum.210912
Tien Nguyen
1T. Nguyen, MD, First OC Dermatology, Irvine, California;
Melvin Churchill
2M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, Nebraska;
Robert Levin
3R. Levin, MD, Clinical Research of West Florida, Inc., Clearwater, Florida, and University of South Florida, Tampa, Florida;
Guillermo Valenzuela
4G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, Florida, USA;
Joseph F. Merola
5J.F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts;
Alexis Ogdie
6A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania;
Ana-Maria Orbai
7A.M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, Maryland;
Jose U. Scher
8J.U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, New York;
Arthur Kavanaugh
9A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, California;
Farid Kianifard
10F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Chauncy Rollins
10F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Renato Calheiros
10F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Olivier Chambenoit
10F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
REFERENCES
- 1.↵
- 2.↵
- 3.↵
- 4.
- 5.↵
- 6.↵
- 7.↵
- Haroon M,
- Gallagher P,
- Fitzgerald O
- 8.↵
- Coates LC,
- Helliwell PS
- 9.↵
- 10.↵
- 11.↵
- 12.
- 13.
- Kivitz AJ,
- Nash P,
- Tahir H, et al
- 14.↵
- Mease P,
- van der Heijde D,
- Landewé R, et al
- 15.
- Reich K,
- Sullivan J,
- Arenberger P, et al
- 16.↵
- Baraliakos X,
- Gossec L,
- Pournara E, et al
- 17.↵
- Mease PJ,
- Kavanaugh A,
- Reimold A, et al; FUTURE 1 study group
- 18.↵
- Kivitz A,
- Kremer J,
- Legerton C, et al
- 19.↵
- 20.↵
- Coates LC,
- Tillett W,
- Shaddick G,
- Pincus T,
- Kavanaugh A,
- Helliwell PS
- 21.↵
- Vakil-Gilani KM,
- Dinno A,
- Rich-Garg N,
- Deodhar A
- 22.↵
- Gottlieb AB,
- Mease PJ,
- Kirkham B, et al
- 23.↵
- Orbai AM,
- Husni ME,
- Gladman DD, et al
- 24.↵
- 25.↵
- 26.↵
- Ogdie A,
- Schwartzman S,
- Eder L, et al
In this issue
The Journal of Rheumatology
Vol. 49, Issue 8
1 Aug 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros, Olivier Chambenoit
The Journal of Rheumatology Aug 2022, 49 (8) 894-902; DOI: 10.3899/jrheum.210912
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros, Olivier Chambenoit
The Journal of Rheumatology Aug 2022, 49 (8) 894-902; DOI: 10.3899/jrheum.210912